It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Some vaccines may reduce the risk of dementia through a double effect in which the jabs help protect the brain through their ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

PHILADELPHIA, April 16, 2025--AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices ...

Cumulatively, the efficacy of a single Arexvy dose to prevent RSV-related lower respiratory tract disease over three RSV seasons was 62.9%. Efficacy over three seasons was 51.1%.

Abrysvo or Arexvy Market Regional and Country Analysis 10.1. Global Abrysvo or Arexvy Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million 10.2.

AREXVY is not approved for use in persons <50 years of age Vaccination with AREXVY may not result in protection of all vaccine recipients Please see full Prescribing Information for AREXVY.

AREXVY is not approved for use in persons <50 years of age Vaccination with AREXVY may not result in protection of all vaccine recipients Please see full Prescribing Information for AREXVY.